Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Clinical Research Center of Hubei Critical Care Medicine, Wuhan, Hubei, China.
PLoS One. 2021 Mar 18;16(3):e0248671. doi: 10.1371/journal.pone.0248671. eCollection 2021.
Thrombocytopenia has been proved to be associated with hospital mortality in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. However, the detailed association of thrombocytopenia with subsequent progression of organ functions and long-term prognosis in critically ill COVID-19 patients remains to be explored.
Medical records of 167 confirmed cases of critically ill COVID-19 from February 16 to March 21, 2020 were collected in this two-center retrospective study. 180-day's outcome and clinical organ development in patients with thrombocytopenia and non-thrombocytopenia were analyzed.
Among all 167 patients, the median age was 66 years and 67.07% were male. Significant differences were noticed in laboratory findings including white blood cells, blood urea, total bilirubin, lactate dehydrogenase and SOFA score between groups of thrombocytopenia and non-thrombocytopenia. Older age, lower platelet count and longer activated partial thromboplastin time at admission were determined to be risk factors of 28-day mortality, and all three, together with higher white blood cells were risk factors of 180-day mortality. Subsequent changes of six-point ordinal scale score, oxygenation index, and SOFA score in patients with thrombocytopenia showed marked worsening trends compared with patients without thrombocytopenia. Patients with thrombocytopenia had significantly higher mortality not only in 28 days, but also in 90 days and 180 days. The time-course curves in non-survival group showed a downtrend of platelet count and oxygenation index, while the curve of six-point ordinal scale kept an uptrend. Kaplan-Meier analysis indicated that patients with thrombocytopenia had much lower probability of survival (p<0.01).
The thrombocytopenia was associated with the deterioration of respiratory function. Baseline platelet count was associated with subsequent and long-term mortality in critically ill COVID-19 patients.
血小板减少已被证明与严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 感染患者的住院死亡率相关。然而,血小板减少与危重症 COVID-19 患者器官功能的后续进展和长期预后的详细关联仍有待探索。
本研究为回顾性的、在两个中心进行的研究,共纳入了 2020 年 2 月 16 日至 3 月 21 日期间确诊的 167 例危重症 COVID-19 患者的病历。分析了血小板减少症和非血小板减少症患者的 180 天预后和临床器官进展情况。
在所有 167 例患者中,中位年龄为 66 岁,67.07%为男性。血小板减少症组和非血小板减少症组在实验室检查结果方面存在显著差异,包括白细胞、血尿素、总胆红素、乳酸脱氢酶和 SOFA 评分。入院时年龄较大、血小板计数较低、活化部分凝血活酶时间较长是 28 天死亡率的危险因素,这三个因素加上白细胞计数较高是 180 天死亡率的危险因素。与无血小板减少症的患者相比,血小板减少症患者的 6 分等级量表评分、氧合指数和 SOFA 评分的后续变化显示出明显的恶化趋势。血小板减少症患者不仅在 28 天,而且在 90 天和 180 天的死亡率均显著升高。非生存组的时间曲线显示血小板计数和氧合指数呈下降趋势,而 6 分等级量表曲线呈上升趋势。Kaplan-Meier 分析表明,血小板减少症患者的生存率显著降低(p<0.01)。
血小板减少与呼吸功能恶化有关。基线血小板计数与危重症 COVID-19 患者的后续和长期死亡率相关。